Fundz

Rezolute

Redwood City, California, United States · Biotechnology, Biotechnology Research, Health Care

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI).

Key facts

Headquarters
Redwood City, California, United States
Employees
64
Industries
Biotechnology, Biotechnology Research, Health Care
Status
Public (RZLT)
Website
rezolutebio.com
LinkedIn
Company page

Recent activity at Rezolute

  • : SEC 8-K (1.01): On November 13, 2026, Rezolute, Inc. entered into a Material Definitive Agreement through an Underwriting Agreement with Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and Cantor Fitzgerald & Co. The agreement pertains to the issuance and sale of 22,040,976 shares of common stock at an offering price of $3.8700 per share and pre-funded warrants to purchase up to 3,800,000 shares at $3.8690 per warrant. The estimated net proceeds from the offering are approximately $93.5 million, intended for commercialization preparation and working capital. The closing is expected on or about November 16, 2026, subject to customary conditions, and includes lock-up provisions for the Company's executive officers and directors for 30 days post-offering.
  • : SEC 8-K (8.01):
  • : SEC 8-K (7.01): Rezolute, Inc. provided a Regulation FD Disclosure concerning its newly prepared Investor Presentation released on October 29, 2026. The presentation materials are intended for use in communications with current and potential investors, analysts, lenders, and other stakeholders interested in the Company. It highlights forward-looking statements and uncertainties pertaining to the Company's future plans and strategies. This report does not constitute a filing under the Securities Exchange Act and includes cautionary statements regarding reliance on the statements made.
  • : SEC 8-K (7.01): On October 14, 2026, Rezolute, Inc. issued a press release regarding an update on patient enrollment in its upLIFT study. The announcement includes forward-looking statements related to the company's expectations and strategic plans for the study. This update is significant for stakeholders as it indicates progress in clinical research, which may affect the company's future operations and financial performance. The press release highlights the company's commitment to transparency and the unpredictable nature of future results. This filing serves to ensure compliance with Regulation FD by disclosing important information to the public.
  • : SEC 8-K (7.01): On October 5, 2026, Rezolute, Inc. issued a press release regarding updates on their ongoing discussions with the FDA concerning the sunRIZE trial. This announcement reflects important developments in the regulatory review process that could significantly impact the company's strategic direction and product pipeline. The communication aims to keep shareholders informed about potential next steps in the trial, which may influence future financial performance. The filing indicates that this update is critical for investors to assess the company's compliance and progress with regulatory requirements. This is a Reg FD Disclosure intended to share material information with all investors.
  • : SEC 8-K (2.02): On September 24, 2026, Rezolute, Inc. announced its financial results for the fourth quarter and fiscal year ended June 30, 2026. This press release provides crucial insights into the company's financial performance over the previous year, detailing revenues, expenses, net income, and other key financial metrics. The announcement is significant for investors and stakeholders as it reflects the company's financial health and strategic direction moving forward. The document attached as Exhibit 99.1 likely includes comprehensive financial statements and management's discussion regarding the results. This filing can impact stock performance and investor sentiment.
  • : SEC 8-K (7.01): On June 2, 2026, Rezolute, Inc. issued a press release providing an interim update on its upLIFT study. This disclosure includes forward-looking statements concerning the Company's plans, strategies, and expectations, cautioning readers about the inherent uncertainties in predicting actual outcomes. The filing emphasizes the need for caution in relying on these projections, referencing specific risk factors included in earlier SEC filings. This update is significant as it provides insights into ongoing research and development, potentially impacting investor sentiment and future company performance.
  • : SEC 8-K (7.01): On May 1, 2026, Rezolute, Inc. issued a press release regarding the results of its Phase 3 sunRIZE study, making important announcements likely relevant to investors and analysts. The press release discusses forward-looking statements regarding the company's strategies and expectations, highlighting the uncertainty inherent in predicting future results. This disclosure is intended to inform stakeholders about the company's recent developments and strategies, emphasizing that actual results may differ from the anticipated outcomes discussed. The filing, made on May 4, 2026, aligns with Regulation FD requirements as it communicates material information to the public.
  • : SEC 8-K (7.01): On March 24, 2026, Rezolute, Inc. issued a press release regarding the results from its recent meeting with the FDA. This event is significant as it involves regulatory communications which could impact the company's future plans and operations. The filing highlights that the information is not deemed 'filed' under the Exchange Act, indicating that while important, it does not carry the formal regulatory burden. The press release includes forward-looking statements about the company's strategies and expectations, with a focus on the uncertainty of predicting future results. The event date directly correlates to the recent disclosure.
  • : SEC 8-K (7.01): On January 7, 2026, Rezolute, Inc. issued a press release providing further insights into the sunRIZE trial, which focused on the use of ersodetug for treating tumors. The release included a cumulative table detailing data from the initial 9 participants in the Expanded Access Program (EAP), highlighting patient characteristics, dosing information, and observed outcomes. Moreover, an updated corporate presentation deck was shared. This disclosure is significant as it communicates ongoing developments in a clinical trial context, which may impact investor perception and market interest.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Rezolute funding history

DateRoundAmount
Oct 2020Venture$41.0M
Feb 2018Seed$500K
Jan 2018Seed$138K
May 2017Venture$6.7M
Feb 2017Seed$3.4M

Leadership

  • Nevan Elam, Executive Officer, Director
  • Gil Labrucherie, Director
  • Philippe Fauchet, Director
  • Jung-Hee Lim, Director
  • Young-Jin Kim, Director
  • Samir Patel, Director
  • David Welch, Director
  • Tae Kim, Director
  • Hoyoung Huh, Executive Officer, Director

Verified email and direct lines for Rezolute’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Companies similar to Rezolute

About Rezolute: questions and answers

What does Rezolute do?

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI).

Where is Rezolute headquartered?

Rezolute is headquartered in Redwood City, California, United States.

How many employees does Rezolute have?

Rezolute has about 64 employees.

Has Rezolute raised funding?

Yes. Fundz has recorded 5 funding events for Rezolute. The most recent, $41.0M, was in Oct 2020.

What is the latest news on Rezolute?

On Oct 17, 2025, SEC 8-K (1.01): On November 13, 2026, Rezolute, Inc. entered into a Material Definitive Agreement through an Underwriting Agreement with Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and Cantor Fitzgerald & Co. The agreement pertains to the issuance and sale of 22,040,976 shares of common st

Is Rezolute a public company?

Yes. Rezolute is publicly traded under the ticker RZLT.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Rezolute across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.